Qualifying Therapeutic Discovery Project Grants for the State of Louisiana
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
|Applicant Name||Project Name||Grants Awarded for 2009||Grants Awarded for 2010|
|Autoimmune Technologies, LLC||Flufirvitide-3: A Broad-Spectrum Entry-inhibiting Seasonal and Pandemic Influenza Drug||$ 216,310.35||$ 28,168.90|
|DEKK-Tec, Inc.||The Clinical Development of 4-Demethylcholesterloxycarbonylpenclomedine.The Clinical Development of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) for the Treatment of Cancers Involving the Central Nervous System||$ 126,990.50||$ 117,488.74|
|Embera Neuro Therapeutics, Inc.||EMB-001: A novel pharmaceutical product for the treatment of addictive disorders||$ 244,479.24|
|Esperance Pharmaceuticals, Inc||The Development of a Cationic Lytic Peptide (CLYPTM) Technology Platform||$ 244,479.24|
|Meta Logos Inc||Trace-level biosensing for early detection, and treatment, of cancer and other diseases.||$ 137,500.00||$ 106,979.24|
|NuPotential,Inc.||A new Approach to Regenerative Medicine Development||$ 244,479.25|
|TCA Cellular Therapy LLC||TCA Cellular Therapies for treatment of cardiovascular and neurological disease.||$ 168,075.93||$ 76,403.32|
|TRANSGENRX, INC.||Engineered glycosylated interferons for the treatment of viral diseases, Melanoma and MS||$ 244,479.25|